3-(2-chlorophenyl)-N-(pyridin-3-ylmethyl)prop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-(2-chlorophenyl)-N-(pyridin-3-ylmethyl)prop-2-enamide
• 化学式: C₁₅H₁₃ClN₂O
• mdl: MFCD01339569
• 分子量: 272.73
• InChiKey: UZAJKTADEDDFNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• METHODS OF TREATING OCULAR DISORDERS
  申请人：Beta Therapeutics Pty. Ltd.

  公开号：EP3554505A1

  公开（公告）日：2019-10-23
• EXTERNAL PREPARATION FOR SKIN
  申请人：Iriyama Shunsuke

  公开号：US20120328719A1

  公开（公告）日：2012-12-27

  An object of the present invention is to provide prevent or improve decreases in the barrier function and moisture retention function of the skin, and that object is achieved by applying an external preparation for skin that comprises a matrix metalloproteinase inhibitor and a heparanase inhibitor.
• Methods of Treating Ocular Disorders
  申请人：NELMS Keats

  公开号：US20200093852A1

  公开（公告）日：2020-03-26

  This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.
• [EN] METHODS OF TREATING OCULAR DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：BETA THERAPEUTICS PTY LTD

  公开号：WO2018107226A1

  公开（公告）日：2018-06-21

  This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age- related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.